Animal models in neurology: Drawbacks and opportunities

Current Pharmaceutical Design

Volumn 18, Issue 29, 2012, Pages 4443-4452

  Patejdl, Robert ^a   Zettl, Uwe K ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Animal models; Encephalitogenic epitopes; Experimental autoimmune encephalomyelitis; Microarray; Multiple sclerosis; Natalizumab; Neurology; Transgene animals

Indexed keywords

ANTIOXIDANT; APTIGANEL; ENLIMOMAB; ERYTHROPOIETIN; FLUNARIZINE; INFLIXIMAB; INTERFERON BETA SERINE; MONOCLONAL ANTIBODY; NATALIZUMAB; NXY 59; ROQUINIMEX; SALAZOSULFAPYRIDINE; SIMVASTATIN; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL MENINGITIS; BRAIN TUMOR; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DENTATORUBROPALLIDOLUYSIAN ATROPHY; DYSTONIA; EPILEPSY; FRIEDREICH ATAXIA; GENETIC MANIPULATION; GUILLAIN BARRE SYNDROME; HEAD INJURY; HUNTINGTON CHOREA; KENNEDY DISEASE; LIPIDOSIS; MICROARRAY ANALYSIS; MUCOPOLYSACCHARIDOSIS; MUCOPOLYSACCHARIDOSIS TYPE 7; MULTIPLE SCLEROSIS; MUSCULAR DYSTROPHY; MYASTHENIA GRAVIS; NEUROLOGIC DISEASE; NEUROLOGY; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RABIES; RESTLESS LEGS SYNDROME; SENILE DEMENTIA; SPINAL CORD INJURY; STROKE; TETANUS; TRANSGENE;

ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES; NEUROLOGY; PARKINSON DISEASE;

EID: 84866391713     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802502233     Document Type: Article

References (151)

1. Iijima K, Iijima-Ando K. Drosophila models of Alzheimer's amyloidosis: the challenge of dissecting the complex mechanisms of toxicity of amyloid-beta 42. J Alzheimers Dis 2008; 15: 523-540.
2. Puccio H. Multicellular models of Friedreich ataxia. J Neurol 2009; 256 (Suppl 1): 18-24.
3. Hünig T. Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. Adv Immunol 2007; 95: 111-148.
4. Ransohoff RM. EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis. Trends Immunol 2006; 27: 167-168.
5. Shuaib A, Lees KR, Lyden P et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007; 357: 562-571.
6. Sriram S, Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol 2005; 58: 939-945.
7. Strauss U, Kole MH, Bräuer AU et al. An impaired neocortical Ih is associated with enhanced excitability and absence epilepsy. Eur J Neurosci 2004; 19: 3048-3058.
8. Mazrier H, Van Hoeven M, Wang P et al. Inheritance, biochemical abnormalities, and clinical features of feline mucolipidosis II: the first animal model of human I-cell disease. J Hered 2003; 94: 363-373.
9. Longa EZ, Weinstein PR, Carlson S et al. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20: 84-91.
10. Kuroiwa T, Xi G, Hua Y et al. Development of a rat model of photothrombotic ischemia and infarction within the caudoputamen. Stroke 2009; 40: 248-253.
11. Moran LB, Graeber MB. The facial nerve axotomy model. Brain Res Brain Res Rev 2004; 44: 154-178.
12. Cernak I. Animal models of head trauma. NeuroRx 2005; 2: 410-422.
13. Kerschensteiner M, Schwab ME, Lichtman JW et al. In vivo imaging of axonal degeneration and regeneration in the injured spinal cord. Nat Med 2005; 11: 572-577.
14. Böttcher T, Ren H, Goiny M et al. Clindamycin is neuroprotective in experimental Streptococcus pneumoniae meningitis compared with ceftriaxone. J Neurochem 2004; 91: 1450-1460.
15. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 1968; 5: 107-110.
16. Beal MF, Ferrante RJ, Swartz KJ et al. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 1991; 11: 1649-1659.
17. Giovanni A, Sonsalla PK, Heikkila RE. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. J Pharmacol Exp Ther 1994; 270: 1008-1014.
18. Mix E, Olsson T, Solders G et al. Effect of ion channel blockers on immune response and course of experimental allergic neuritis. Brain 1989; 112 (Pt 6): 1405-1418.
19. Christadoss P, Poussin M, Deng C. Animal models of myasthenia gravis. Clin Immunol 2000; 94: 75-87.
20. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006; 129: 1953-1971.
21. Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 2006; 60: 12-21.
22. Mix E, Meyer Rienecker H, Zettl UK. Animal models of multiple sclerosis for the development and validation of novel therapies -potentials and limitations. J Neurol 2008; 255 Suppl 6: 7-14.
23. Owens T, Wekerle H, Antel J. Genetic models for CNS inflammation. Nat Med 2001; 7: 161-166.
24. von Hörsten S, Schmitt I, Nguyen HP et al. Transgenic rat model of Huntington's disease. Hum Mol Genet 2003; 12: 617-624.
25. Awasthi A, Riol-Blanco L, Jäger A et al. Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells. J Immunol 2009; 182: 5904-5908.
26. Baloh RH, Strickland A, Ryu E et al. Congenital hypomyelinating neuropathy with lethal conduction failure in mice carrying the Egr2 I268N mutation. J Neurosci 2009; 29: 2312-2321.
27. Schenkel J. Transgene Tiere. Heidelberg: Springer 2006.
28. Friese MA, Jakobsen KB, Friis L et al. Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis. Nat Med 2008; 14: 1227-1235.
29. Krishnamoorthy G, Holz A, Wekerle H. Experimental models of spontaneous autoimmune disease in the central nervous system. J Mol Med 2007; 85: 1161-1673.
30. Yamada M, Sato T, Tsuji S et al. CAG repeat disorder models and human neuropathology: similarities and differences. Acta Neuropathol 2008; 115: 71-86.
31. Amann D. www.gentechnologie.ch/papiere/krankheitsmodelle03.pdf 2003.
32. Ulzheimer JC, Meuth SG, Bittner S et al. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies. BioDrugs 2010; 24: 249-274.
33. Philip M, Benatar M, Fisher M et al. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke 2009; 40: 577-581.
34. Ibrahim SM, Mix E, Böttcher T et al. Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain 2001; 124: 1927-1938.
35. Serrano-Fernández P, Ibrahim SM, Zettl UK et al. Intergenomic consensus in multifactorial inheritance loci: the case of multiple sclerosis. Genes Immun 2004; 5: 615-620.
36. Mazón Peláez I, Vogler S, Strauss U et al. Identification of quantitative trait loci controlling cortical motor evoked potentials in experimental autoimmune encephalomyelitis: correlation with incidence, onset and severity of disease. Hum Mol Genet 2005; 14: 1977-1989.
37. Fernald GH, Yeh R, Hauser SL et al. Mapping gene activity in complex disorders: Integration of expression and genomic scans for multiple sclerosis. J Neuroimmunol 2005; 167: 157-169.
38. Möller S, Zettl UK, Serrano-Fernández P et al. Comparative genomics for the investigation of autoimmune diseases. Curr Pharm Des 2006; 12: 3707-3722.
39. Zorzella SF, Seger J, Martins DR et al. Resistance to experimental autoimmune encephalomyelitis development in Lewis rats from a conventional animal facility. Mem Inst Oswaldo Cruz 2007; 102: 931-936.
40. Lam CK, Yoo T, Hiner B et al. Embolus extravasation is an alternative mechanism for cerebral microvascular recanalization. Nature 2010; 465: 478-482.
41. Zettl UK, Gold R, Toyka KV et al. Intravenous glucocorticosteroid treatment augments apoptosis of inflammatory T cells in experimental autoimmune neuritis (EAN) of the Lewis rat. J Neuropathol Exp Neurol 1995; 54: 540-547.
42. Benecke R, Takano K, Schmidt J et al. Tetanus toxin induced actions on spinal Renshaw cells and Ia-inhibitory interneurones during development of local tetanus in the cat. Exp Brain Res 1977; 27: 271-286.
43. Iwasaki T. Contribution of experimental paradigms of viral infectious diseases to diagnostic pathology. Semin Diagn Pathol 2007; 24: 237-242.
44. McArthur R, Borsini F. Animal and translational models for CNS drug discovery. Elsevier, Amsterdam 2008.
45. Lock C, Hermans G, Pedotti R et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8: 500-508.
46. Butti E, Bergami A, Recchia A et al. IL4 gene delivery to the CNS recruits regulatory T cells and induces clinical recovery in mouse models of multiple sclerosis. Gene Ther 2008; 15: 504-515.
47. Lundberg C, Björklund T, Carlsson T et al. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr Gene Ther 2008; 8: 461-473.
48. Henning J, Koczan D, Glass A et al. Deep brain stimulation in a rat model modulates TH, CaMKIIa and Homer1 gene expression. Eur J Neurosci 2007; 25: 239-250.
49. Kappos L, Comi G, Panitch H et al. Induction of a nonencephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 2000; 6: 1176-1182.
50. Stüve O, Gold R, Chan A et al. Alpha4-Integrin antagonism with natalizumab: effects and adverse effects. J Neurol 2008; 255 Suppl 6: 58-65.
51. Morrissey SP, Stodal H, Zettl UK et al. In vivo MRI and its histological correlates in acute adoptive transfer experimental allergic encephalomyelitis. Quantification of inflammation and oedema. Brain 1996; 119 (Pt 1): 239-248.
52. Luo J, Ho P, Steinman L et al. Bioluminescence in vivo imaging of autoimmune encephalomyelitis predicts disease. J Neuroinflammation 2008; 5: 6.
53. Lavi E, Constantinescu SC. Experimental models of multiple sclerosis. 2005;:
54. Lindsey J. EAE: history, clinical signs, and disease course. In: Lavi E, Constantinescu CS. Eds.: Experimental models of multiple sclerosis. New York: Springer 2005; pp. 1-9.
55. Rivers T, Sprunt D, Berry GP. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J Exp Med 1933; 58: 39-53.
56. Koritschoner R, Schweinburg F. Klinische und experimentelle Beobachtungen über Lähmungen nach Wutschutzimpfung. Z. Immunitäts-Forsch. 1925; 422: 217-283.
57. Wekerle H, Kojima K, Lannes-Vieira J et al. Animal models. Ann Neurol 1994; 36 Suppl: S47-S53.
58. Olsson T, Dahlman I, Wallström E et al. Genetics of rat neuroinflammation. J Neuroimmunol 2000; 107: 191-200.
59. Hartung HP, Kieseier BC, Hemmer B. Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis. J Neurol 2005; 252 Suppl 5: v30-v37.
60. Mix E, Meyer-Rienecker H, Hartung HP et al. Animal models of multiple sclerosis-Potentials and limitations. Prog Neurobiol 2010; In press:.
61. Miljkovic D, Stosic-Grujicic S, Markovic M et al. Strain difference in susceptibility to experimental autoimmune encephalomyelitis between Albino Oxford and Dark Agouti rats correlates with disparity in production of IL-17, but not nitric oxide. J Neurosci Res 2006; 84: 379-388.
62. Mix E, Ibrahim S, Pahnke J et al. Gene-expression profiling of the early stages of MOG-induced EAE proves EAE-resistance as an active process. J Neuroimmunol 2004; 151: 158-170.
63. Ford ML, Evavold, BD. Specificity, magnitude, and kinetics of MOG-specific CD8+ T cell responses during experimental autoimmune encephalomyelitis. Eur J Immunol 2005; 35: 76-85.
64. Barcellos LF, Sawcer S, Ramsay PP et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 2006; 15: 2813-2824.
65. Khare M, Mangalam A, Rodriguez M et al. HLA DR and DQ interaction in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in HLA class II transgenic mice. J Neuroimmunol 2005; 169: 1-12.
66. Jagodic M, Kornek B, Weissert R et al. Congenic mapping confirms a locus on rat chromosome 10 conferring strong protection against myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. Immunogenetics 2001; 53: 410-415.
67. de Rosbo NK, Kaye JF, Eisenstein M et al. The myelin-associated oligodendrocytic basic protein region MOBP15-36 encompasses the immunodominant major encephalitogenic epitope(s) for SJL/J mice and predicted epitope(s) for multiple sclerosis-associated HLA-DRB1*1501. J Immunol 2004; 173: 1426-1435.
68. Gould K, Stepaniak J, Swanborg RH. Variable susceptibility of Lewis rats to experimental autoimmune encephalomyelitis. J Neuroimmunol 1994; 54: 145-146.
69. Baranzini SE, Mousavi P, Rio J et al. Transcription-based prediction of response to IFNbeta using supervised computational methods. PLoS Biol 2005; 3: e2.
70. Mix E, Meyer-Rienecker H, Hartung HP et al. Animal models of multiple sclerosis--potentials and limitations. Prog Neurobiol 2010; 92: 386-404.
71. Wiendl H, Toyka KV, Rieckmann P et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008; 255: 1449-1463.
72. Kieseier BC, Hartung HP. Current disease-modifying therapies in multiple sclerosis. Semin Neurol 2003; 23: 133-146.
73. Aharoni R, Teitelbaum D, Sela M et al. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 1997; 94: 10821-1086.
74. Racke MK, Lovett-Racke AE, Karandikar NJ. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology 2010; 74 Suppl 1: S25-S30.
75. Neuhaus O, Wiendl H, Kieseier BC et al. Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 2005; 168: 128-137.
76. Yednock TA, Cannon C, Fritz LC et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63-66.
77. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353: 369-374.
78. Schmidt J, Gold R, Schönrock L et al. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 2000; 123 (Pt 7): 1431-1441.
79. Steinman L. Mixed results with modulation of TH-17 cells in human autoimmune diseases. Nat Immunol 2010; 11: 41-44.
80. Bielekova B, Kadom N, Fisher E et al. MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology 2005; 65: 1071-1076.
81. Beyer S, Mix E, Hoffrogge R et al. Neuroproteomics in stem cell differentiation. Proteomics Clin Appl 2007; 1: 1513-1523.
82. Schrader M, Selle H. The process chain for peptidomic biomarker discovery. Dis Markers 2006; 22: 27-37.
83. Martin R, Bielekova B, Hohlfeld R et al. Biomarkers in multiple sclerosis. Dis Markers 2006; 22: 183-185.
84. Marek K, Jennings D, Tamagnan G et al. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression. Ann Neurol 2008; 64 Suppl 2: S111-S121.
85. Melrose HL, Lincoln SJ, Tyndall GM et al. Parkinson's disease: a rethink of rodent models. Exp Brain Res 2006; 173: 196-204.
86. Jenner P. Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. Ann Neurol 2008; 64 Suppl 2: S16-S29.
87. van der Worp HB, Howells DW, Sena ES et al. Can animal models of disease reliably inform human studies?. PLoS Med 2010; 7(3): e1000245.
88. Mitchell KJ, Huang ZJ, Moghaddam B et al. Following the genes: a framework for animal modeling of psychiatric disorders. BMC Biol 2011; 9: 76.
89. Dickerson DD, Restieaux AM, Bilkey DK. Clozapine administration ameliorates disrupted long-range synchrony in a neurodevelopmental animal model of schizophrenia. Schizophr Res 2012; epub.
90. Wohlfarth K, Göschel H, Frevert J et al. Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 1997; 355: 335-340.
91. Hadjilambreva G, Mix E, Rolfs A et al. Neuromodulation by a cytokine: interferon-beta differentially augments neocortical neuronal activity and excitability. J Neurophysiol 2005; 93: 843-852.
92. Moroni F, Formentini L, Gerace E et al. Selective PARP-2 inhibitors increase apoptosis in hippocampal slices but protect cortical cells in models of post-ischaemic brain damage. Br J Pharmacol 2009; 157: 854-862.
93. Rowe L, Almasri M, Lee K et al. Active 3-D microscaffold system with fluid perfusion for culturing in vitro neuronal networks. Lab Chip 2007; 7: 475-482.
94. Gross GW. Simultaneous single unit recording in vitro with a photoetched laser deinsulated gold multimicroelectrode surface. IEEE Trans Biomed Eng 1979; 26: 273-279.
95. Gramowski A, Jügelt K, Stüwe S et al. Functional screening of traditional antidepressants with primary cortical neuronal networks grown on multielectrode neurochips. Eur J Neurosci 2006; 24: 455-465.
96. Koester P, Sakowski J, Baumann W et al. A new exposure system for the in vitro detection of GHz field effects on neuronal networks. Bioelectrochemistry 2007; 70: 104-114.
97. The touch program. www.tysabri.com
98. Lu M, Duan R, Quezada HC et al. Aggravation of experimental autoimmune neuritis in TNF-alpha receptor 1 deficient mice. J Neuroimmunol 2007; 186: 19-26.
99. Zhu J, Mix E, Link, H. Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome. J Neuroimmunol 1998; 84: 40-52.
100. Grieb P. Transgenic models of amyotrophic lateral sclerosis. Folia Neuropathol 2004; 42: 239-248.
101. Kragh PM, Nielsen AL, Li J et al. Hemizygous minipigs produced by random gene insertion and handmade cloning express the Alzheimer's disease-causing dominant mutation APPsw. Transgenic Res 2009; 18: 545-558.
102. Sarasa M, Pesini P. Natural non-trasgenic animal models for research in Alzheimer's disease. Curr Alzheimer Res 2009; 6: 171-178.
103. Pahnke J, Wolkenhauer O, Krohn M et al. Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2008; 5: 396-405.
104. Woodruff-Pak DS. Animal models of Alzheimer's disease: therapeutic implications. J Alzheimers Dis 2008; 15: 507-521.
105. Zhang Q, Ding H, Li W et al. Senescence accelerated mouse strain is sensitive to neurodegeneration induced by mild impairment of oxidative metabolism. Brain Res 2009; 1264: 111-118.
106. Scherzer CR, Jensen RV, Gullans SR et al. Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease. Hum Mol Genet 2003; 12: 2457-2466.
107. Nuber S, Petrasch-Parwez E, Winner B et al. Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. J Neurosci 2008; 28: 2471-2484.
108. Allen RP, Earley, CJ. The role of iron in restless legs syndrome. Mov Disord 2007; 22 Suppl 18: S440-S448.
109. Bates GP, Mangiarini L, Davies SW. Transgenic mice in the study of polyglutamine repeat expansion diseases. Brain Pathol 1998; 8: 699-714.
110. Menini C, Silva-Barrat, C. Value of the monkey Papio papio for the study of epilepsy. Pathol Biol (Paris) 1990; 38: 205-213.
111. Chen Z, Ljunggren H, Bogdanovic N et al. Excitotoxic neurodegeneration induced by intranasal administration of kainic acid in C57BL/6 mice. Brain Res 2002; 931: 135-145.
112. Schubert M, Siegmund H, Pape H et al. Kindling-induced changes in plasticity of the rat amygdala and hippocampus. Learn Mem 2005; 12: 520-526.
113. Locke CJ, Williams SN, Schwarz EM et al. Genetic interactions among cortical malformation genes that influence susceptibility to convulsions in C. elegans. Brain Res 2006; 1120: 23-34.
114. Sharma AK, Reams RY, Jordan WH et al. Mesial temporal lobe epilepsy: pathogenesis, induced rodent models and lesions. Toxicol Pathol 2007; 35: 984-999.
115. Wynshaw-Boris A. Lissencephaly and LIS1: insights into the molecular mechanisms of neuronal migration and development. Clin Genet 2007; 72: 296-304.
116. Aguzzi A, Sigurdson C, Heikenwaelder, M. Molecular mechanisms of prion pathogenesis. Annu Rev Pathol 2008; 3: 11-40.
117. Raike RS, Jinnah HA, Hess, EJ. Animal models of generalized dystonia. NeuroRx 2005; 2: 504-512.
118. Grundmann K, Reischmann B, Vanhoutte G et al. Overexpression of human wildtype torsinA and human DeltaGAG torsinA in a transgenic mouse model causes phenotypic abnormalities. Neurobiol Dis 2007; 27: 190-206.
119. Bilzer T, Reifenberger G, Wechsler W. Chemical induction of brain tumors in rats by nitrosoureas: molecular biology and neuropathology. Neurotoxicol Teratol 1989; 11: 551-556.
120. Huse JT, Holland, Eric C. Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol 2009; 19: 132-143.
121. Kunkel LM, Bachrach E, Bennett RR et al. Diagnosis and cellbased therapy for Duchenne muscular dystrophy in humans, mice, and zebrafish. J Hum Genet 2006; 51: 397-406.
122. Haskins ME. Animal models for mucopolysaccharidosis disorders and their clinical relevance. Acta Paediatr Suppl 2007; 96: 56-62.
123. Jones I, He X, Katouzian F et al. Characterization of common SMPD1 mutations causing types A and B Niemann-Pick disease and generation of mutation-specific mouse models. Mol Genet Metab 2008; 95: 152-162.
124. Eltayeb R, Sharafeldin A, Jaster R et al. Trypanosoma brucei brucei induces interferon-gamma expression in rat dorsal root ganglia cells via a tyrosine kinase-dependent pathway. J Infect Dis 2000; 181: 400-404.
125. Charles P, Tait S, Faivre-Sarrailh C et al. Neurofascin is a glial receptor for the paranodin/Caspr-contactin axonal complex at the axoglial junction. Curr Biol 2002; 12: 217-220.
126. Derfuss T, Linington C, Hohlfeld R et al. Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury. J Mol Med 2010; 88: 753-761.
127. Mathey EK, Derfuss T, Storch MK et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007; 204: 2363-2372.
128. Hedstrom KL, Xu X, Ogawa Y et al. Neurofascin assembles a specialized extracellular matrix at the axon initial segment. J Cell Biol 2007; 178: 875-886.
129. Krishnamoorthy G, Saxena A, Mars LT et al. Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat Med 2009; 15: 626-632.
130. Derfuss T, Parikh K, Velhin S et al. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and medi ates gray matter pathology in animals. Proc Natl Acad Sci U S A 2009; 106: 8302-8307.
131. Mörtl M, Sonderegger P, Diederichs K et al. The crystal structure of the ligand-binding module of human TAG-1 suggests a new mode of homophilic interaction. Protein Sci 2007; 16: 2174-2183.
132. Shimoda Y, Watanabe K. Contactins: emerging key roles in the development and function of the nervous system. Cell Adh Migr 2009; 3: 64-70.
133. Kojima K, Wekerle H, Lassmann H et al. Induction of experimental autoimmune encephalomyelitis by CD4+ T cells specific for an astrocyte protein, S100 beta. J Neural Transm Suppl 1997; 49: 43-51.
134. Ohler B, Graf K, Bragg R et al. Role of lipid interactions in autoimmune demyelination. Biochim Biophys Acta 2004; 1688: 10-17.
135. Kanter JL, Narayana S, Ho PP et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med 2006; 12: 138-143.
136. Qin J, Goswami R, Balabanov R et al. Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain. J Neurosci Res 2007; 85: 977-984.
137. Shamshiev A, Donda A, Carena I et al. Self glycolipids as T-cell autoantigens. Eur J Immunol 1999; 29: 1667-1675.
138. Pender MP, Csurhes PA, Wolfe NP et al. Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. J Clin Neurosci 2003; 10: 63-66.
139. Matà S, Lolli F, Söderström M et al. Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD1a. Mult Scler 1999; 5: 379-388.
140. Quintana FJ, Farez MF, Viglietta V et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A 2008; 105: 18889-18894.
141. Winkelmann A, Patejdl R, Wagner S et al. Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy. J Neurol 2008; 255 Suppl 6: 109-1014.
142. van Oosten BW, Barkhof F, Truyen L et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47: 1531-1534.
143. Faria A, Weiner, Howard L. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol 2006; 13: 143-157.
144. Noseworthy JH, O'Brien P, Erickson BJ et al. The Mayo Clinic- Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology 1998; 51: 1342-1352.
145. Noseworthy JH, Wolinsky JS, Lublin FD et al. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology 2000; 54: 1726-1733.
146. Sorensen PS, Lycke J, Erälinna J et al. Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol 2011; 10(8): 691-701.
147. Digicaylioglu M. Erythropoietin in stroke: quo vadis. Expert Opin Biol Ther 2010; 10: 937-949.
148. Ehrenreich H, Weissenborn K, Prange H et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009; 40: e647-e656.
149. Franke CL, Palm R, Dalby M et al. Flunarizine in stroke treatment (FIST): a double-blind, placebo-controlled trial in Scandinavia and the Netherlands. Acta Neurol Scand 1996; 93: 56-60.
150. Albers GW, Goldstein LB, Hall D et al. Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. JAMA 2001; 286: 2673-2682.
151. Schneider D, Berrouschot J, Brandt T et al. Safety, pharmacokinetics and biological activity of enlimomab (anti-ICAM-1 antibody):an open-label, dose escalation study in patients hospitalized for acute stroke. Eur Neurol 1998; 40: 78-83.